Effect of thioredoxin reductase 1 on glucocorticoid receptor activity in human outer root sheath cells

Biochemical and Biophysical Research Communications

Volumn 356, Issue 3, 2007, Pages 810-815

  Sohn, Kyung Cheol ^a   Jang, Sunhyae ^a   Choi, Dae Kyoung ^a   Lee, Young Sook ^a   Yoon, Tae Jin ^b   Jeon, Eun Kyoung ^a   Kim, Kyung Ho ^a   Seo, Young Joon ^a   Lee, Jeung Hoon ^a   Park, Jang Kyu ^a   Kim, Chang Deok ^a  

^a Chungnam National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

Author keywords

Glucocorticoid receptor activity; Glucocorticoid resistant alopecia areata; Thioredoxin reductase 1

Indexed keywords

GLUCOCORTICOID RECEPTOR; HYDROGEN PEROXIDE; THIOREDOXIN; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG;

ALOPECIA AREATA; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HAIR ROOT; HORMONE RECEPTOR INTERACTION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALOPECIA AREATA; DRUG RESISTANCE; HAIR FOLLICLE; HUMANS; HYDROGEN PEROXIDE; IMMUNOHISTOCHEMISTRY; RECEPTORS, GLUCOCORTICOID; SCALP; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH);

EID: 33947667801     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.03.065     Document Type: Article

References (33)

1. Martinez-Mir A., Zlotogorski A., Ott J., Gordon D., and Christiano A.M. Genetic linkage studies in alopecia areata. J. Investig. Dermatol. Symp. Proc. 8 (2003) 199-203
2. Price V.H. Alopecia areata: clinical aspects. J. Invest. Dermatol. 96 (1991) 68S
3. Sawaya M.E., and Hordinsky M.K. Advances in alopecia areata and androgenetic alopecia. Adv. Dermatol. 7 (1992) 211-226
4. Safavi K.H., Muller S.A., Suman V.J., Moshell A.N., and Melton L.J. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin. Proc. 70 (1995) 628-633
5. Madani S., and Shapiro J. Alopecia areata update. J. Am. Acad. Dermatol. 42 (2000) 549-566
6. Papadopoulos A.J., Schwartz R.A., and Janniger C.K. Alopecia areata. Pathogenesis, diagnosis, and therapy. Am. J. Clin. Dermatol. 1 (2000) 101-105
7. Gill Jr. K.A., and Baxter D.L. Alopecia totalis. Treatment with fluocinolone acetonide. Arch. Dermatol. 87 (1963) 384-386
8. Mitchell A.J., and Douglass M.C. Topical photochemotherapy for alopecia areata. J. Am. Acad. Dermatol. 12 (1985) 644-649
9. Fiedler-Weiss V.C., and Buys C.M. Evaluation of anthralin in the treatment of alopecia areata. Arch. Dermatol. 123 (1987) 1491-1493
10. Shapiro J. Topical immunotherapy in the treatment of chronic severe alopecia areata. Dermatol. Clin. 11 (1993) 611-617
11. Shapiro J., Lui H., Tron V., and Ho V. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J. Am. Acad. Dermatol. 36 (1997) 114-117
12. Kiesch N., Stene J.J., Goens J., Vanhooteghem O., and Song M. Pulse steroid therapy for children's severe alopecia areata?. Dermatology 194 (1997) 395-397
13. Rokhsar C.K., Shupack J.L., Vafai J.J., and Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J. Am. Acad. Dermatol. 39 (1998) 751-761
14. Porter D., and Burton J.L. Comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br. J. Dermatol. 85 (1971) 272-273
15. Sawaya M.E., and Hordinsky M.K. Glucocorticoid regulation of hair growth in alopecia areata. J. Invest. Dermatol. 104 (1995) 30S
16. Philpott M.P., Green M.R., and Kealey T. Human hair growth in vitro. J. Cell Sci. 97 (1990) 463-471
17. Hirota K., Matsui M., Iwata S.O., Nishiyama A., Mori K., and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 94 (1997) 3633-3638
18. Ichiki H., Hoshino T., Kinoshita T., Imaoka H., Kato S., Inoue H., Nakamura H., Yodoi J., Young H.A., and Aizawa H. Thioredoxin suppresses airway hyperresponsiveness and airway inflammation in asthma. Biochem. Biophys. Res. Commun. 334 (2005) 1141-1148
19. Pahl H.L., and Baeuerle P.A. Oxygen and the control of gene expression. Bioessays 16 (1994) 497-502
20. Wang H.C., Zentner M.D., Deng H.T., Kim K.J., Wu R., Yang P.C., and Ann D.K. Oxidative stress disrupts glucocorticoid hormone-dependent transcription of the amiloride-sensitive epithelial sodium channel alpha-subunit in lung epithelial cells through ERK-dependent and thioredoxin-sensitive pathways. J. Biol. Chem. 275 (2000) 8600-8609
21. Nalvarte I., Damdimopoulos A.E., Nystom C., Nordman T., Miranda-Vizuete A., Olsson J.M., Eriksson L., Bjornstedt M., Arner E.S., and Spyrou G. Overexpression of enzymatically active human cytosolic and mitochondrial thioredoxin reductase in HEK-293 cells. Effect on cell growth and differentiation. J. Biol. Chem. 279 (2004) 54510-54517
22. Gasdaska J.R., Harney J.W., Gasdaska P.Y., Powis G., and Berry M.J. Regulation of human thioredoxin reductase expression and activity by 3′-untranslated region selenocysteine insertion sequence and mRNA instability elements. J. Biol. Chem. 274 (1999) 25379-25385
23. De Bosscher K., Vanden Berghe W., and Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24 (2003) 488-522
24. De Bosscher K., Vanden Berghe W., and Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J. Neuroimmunol. 109 (2000) 16-22
25. Cato A.C., and Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 18 (1996) 371-378
26. Schaaf M.J., and Cidlowski J.A. Molecular mechanisms of glucocorticoid action and resistance. J. Steroid Biochem. Mol. Biol. 83 (2002) 37-48
27. Zhong L., Arner E.S., and Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc. Natl. Acad. Sci. USA 97 (2000) 5854-5859
28. Mustacich D., and Powis G. Thioredoxin reductase. Biochem. J. 346 (2000) 1-8
29. Powis G., Mustacich D., and Coon A. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic. Biol. Med. 29 (2000) 312-322
30. Xia L., Nordman T., Olsson J.M., Damdimopoulos A., Bjorkhem-Bergman L., Nalvarte I., Eriksson L.C., Arner E.S., Spyrou G., and Bjornstedt M. The mammalian cytosolic selenoenzyme thioredoxin reductase reduces ubiquinone. A novel mechanism for defense against oxidative stress. J. Biol. Chem. 278 (2003) 2141-2146
31. Becker K., Gromer S., Schirmer R.H., and Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur. J. Biochem. 267 (2000) 6118-6125
32. Makino Y., Okamoto K., Yoshikawa N., Aoshima M., Hirota K., Yodoi J., Umesono K., Makino I., and Tanaka H. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J. Clin. Invest. 98 (1996) 2469-2477
33. Makino Y., Yoshikawa N., Okamoto K., Hirota K., Yodoi J., Makino I., and Tanaka H. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J. Biol. Chem. 274 (1999) 3182-3188